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Abstract
Background: Chronic UV skin exposure leads to epidermal differentiation defects in humans that can be largely restored by
pharmacological doses of nicotinic acid. Nicotinic acid has been identified as a ligand for the human G-protein-coupled
receptors GPR109A and GPR109B that signal through Gi-mediated inhibition of adenylyl cyclase. We have examined the
expression, cellular distribution, and functionality of GPR109A/B in human skin and skin derived epidermal cells.
Results: Nicotinic acid increases epidermal differentiation in photodamaged human skin as judged by the terminal
differentiation markers caspase 14 and filaggrin. Both GPR109A and GPR109B genes are transcribed in human skin and in
epidermal keratinocytes, but expression in dermal fibroblasts is below limits of detection. Receptor transcripts are greatly
over-expressed in squamous cell cancers. Receptor protein in normal skin is prominent from the basal through granular
layers of the epidermis, with cellular localization more dispersive in the basal layer but predominantly localized at the
plasma membrane in more differentiated epidermal layers. In normal human primary and immortalized keratinocytes,
nicotinic acid receptors show plasma membrane localization and functional Gi-mediated signaling. In contrast, in a
squamous cell carcinoma derived cell line, receptor protein shows a more diffuse cellular localization and the receptors are
nearly non-functional.
Conclusions: The results of these studies justify future genetic and pharmacological intervention studies to define possible
specific role(s) of nicotinic acid receptors in human skin homeostasis.
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Introduction
The skin functions as a metabolically active biological barrier
protecting against external environmental insults. The mainte-
nance of the skin barrier is critical as many dermatological diseases
are characterized by defective barrier integrity resulting in a
diminished protective capacity of the skin. Skin barrier formation
is characterized by a process of homeostasis where dividing cells in
the basal layer continually migrate toward the skin surface and
undergo terminal differentiation and ultimately planned cell death
to form the stratum corneum composed of terminally differenti-
ated keratinocytes and other substances that form the barrier [1].
However, epidermal proliferation and differentiation must be
carefully balanced since inadequate proliferation results in a
thinning of the epidermal layer of skin and loss of barrier
protection while increased proliferation without coordinate
increased differentiation leads to disorders such as psoriasis and
skin cancers [1].
A major environmental threat resulting in multiple alterations in
skin structure and function is the exposure to ultraviolet light from
the sun [2]. Chronic solar light exposure can ultimately lead to
epidermal hyperproliferation with impaired differentiation result-
ing in actinic keratosis (AK) lesions and squamous cell carcinoma
(SCC) of the skin. The main histological characteristic of SCC is
substitution of normal matured epidermal keratinocytes with
poorly differentiated atypical squamous cells [3]. Mudgil et al.
have demonstrated in skin epidermal equivalents that transformed,
poorly differentiated keratinocytes can be driven to differentiate in
the presence of sufficient numbers of normal keratinocytes [4].
These observations suggest that treatments that could promote
epidermal differentiation in photodamaged skin have the potential
to restore the balance of proliferation and differentiation required
for maintaining skin homeostasis and thus could counteract the
development of AK lesions and SCC.
One of the pharmacological effects of nicotinic acid on photo-
damaged skin is to promote epidermal differentiation [5], raising
the possibility that a nicotinic acid receptor may be involved. The
receptor termed GPR109A (HM74A in humans and PUMA-G in
mice), recently given the HGNC designation of NIACR1, was
discovered in highly differentiated adipocytes, spleen, and immune
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inhibitory G protein, that upon ligand binding signals the decrease
of adenosine 39,59-cyclic monophosphate (cAMP) production via
the inhibition of adenylyl cyclase in a pertussis toxin-sensitive
manner [6,7,8]. GPR109A is a member of a subfamily of
G-protein-coupled receptors (GPCR) composed of GPR109A
and GPR81 both of which are found in humans and rodents.
GPR109B (also termed HM74) is another member of this receptor
family that binds albeit with low affinity to nicotinic acid and is
only present in humans. Nicotinic acid activates both GPR109A
and GPR109B with EC50 values of 0.1 mM and 100 mM,
respectively [9]. While it is considered unlikely that nicotinic acid
is the endogenous ligand of these receptors, pharmacological doses
of nicotinic acid acting through GPR109A mediate both desired
anti-lipolytic effects as well as unwanted cutaneous vasodilatation
effects associated with oral nicotinic acid therapy [6,7,8,10,11].
Since nicotinic acid-induced prostanoid formation responsible for
skin flushing has been suggested to take place in dermal dendritic
Langerhans cells, the expression of GPR109A in skin has been
studied in this context [10,12,13,14]; however, little is known
about the functions of nicotinic acid receptors in other aspects of
skin biology. Here we examine the expression, cellular distribu-
tion, and functionality of GPR109A and GPR109B in skin and
skin derived cells. Our results show that squamous cell cancers
have abnormal GPR109A/B expression, cellular distribution, and
function, indicating that these receptors are involved in skin
homeostasis.
Materials and Methods
Cell Culture
Normal human epidermal keratinocytes (NHEK, Lonza, Swit-
zerland) were routinely cultured in EpiLife (GIBCO/Invitrogen)
containing human keratinocyte growth supplement for less than 10
population doublings. Normal human diploid fibroblasts, CF3,
(population doublings less than 30, Oklahoma Medical Research
Foundation, Oklahoma City, OK), the established cell line of
immortalized human epidermal keratinocytes, HaCaT, and Ras-
transformed HaCaT, gifts from Dr. Norbert Fusenig (German
Cancer Research Center, Heidelberg, Germany) [15], the human
epidermoid carcinoma cell line, A-431 (American Type Culture
Collection (ATCC), Manassas, VA), and the squamous cell
carcinoma cell line, SCC-25 (ATCC) were routinely cultured in
Dulbecco’s Modified Eagle Medium (DMEM, Sigma Aldrich, St.
Louis, MO) containing 10% fetal bovine serum (FBS, Hyclone/
Fisher Scientific). All cells were kept in a humidified atmosphere
containing 5% CO2 at 37uC.
Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR)
Total RNA from adipose tissue, placenta, lung, and skin were
purchased from Stratagene (Cedar Creek, TX) and 1 mg of each
RNA was used to perform cDNA syntheses using the TaqMan
Reverse Transcription kit from Applied Biosystems (Foster City,
CA).PCRwas performed usingthefollowingprimers forGPR109A
and GPR109B: GPR109A – forward – 59 CACCACACAGACA-
CACACCTCCTTGCTGG 39, GPR109B – forward – 59 CAC-
CATACAGACACACGCCACTTTGCTGG 39, and the reverse
primer for both genes – 59 CAGTGACATTACTCGATGCAA-
CAGCCCAAC 39 synthesized by Integrated DNA Technologies
(IDT, Coralville, IA). Thermal cycling conditions were as follows:
activation of DNA polymerase at 94uC for 1 min, followed by 25
cycles of amplification at 94uC for 1 min and 62uC and 68uC for
1 min each.
Quantitative RT-PCR (qRT-PCR)
Total RNA from cultured cells was prepared using the RNeasy
Mini Kit purification system (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. Frozen achieved human normal
skin biopsies, AKs, and SCCs were obtained from the project
entitled ‘‘Chemoprevention of Skin Cancer Program Project
Archived Samples for Additional Analyses, reviewed by the
University of Arizona IRB (Tucson, AZ), Project Number 08-
0201-04. The study from which the samples were obtained was
conducted according to the Declaration of Helsinki Principles.
Written informed consent was obtained from all subjects. Total
RNA from skin tissue samples was prepared using the RNeasy
Fibrous Tissue Mini Kit (Qiagen) following the manufacturer’s
protocol. cDNA synthesis was performed using the TaqMan
Reverse Transcription kit (Applied Biosystems, Foster City, CA)
according to manufacturer’s instructions using random hexamers
and 1 mg of total RNA. For TaqMan-based qRT-PCR expression
profiling, 25 ng of each cDNA including total RNA from
squamous cell carcinoma samples (Asterand, Detroit, MI) was
added to the iTaq Supermix (BioRad, Hercules, CA) along with
the TaqMan MGB probes according to the manufacturer’s
protocol (Applied Biosystems, Foster City, CA). qRT-PCR was
performed as previously described [16]. Probes designed to
specifically detect human GPR109A (TaqMan Gene Expression
Assay Hs02341584_s1) and GPR109B (TaqMan Gene Expression
Assay Hs02341102_s1) transcripts were purchased from Applied
Biosystems. Real-time fluorescence monitoring was performed
with the ABI Prism 7000 (Applied Biosystems). In human skin
tissues, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and
b-actin gene expression changed with the degree of malignancy
compared to 18s rRNA, which remained constant. In cultured
cells, GAPDH and b-actin expression remained constant when
compared to 18s rRNA; therefore relative expression levels of the
various transcripts were determined by comparison against the
housekeeping genes, 18s rRNA for tissues and GAPDH for
cultured cells. All expression measurements were performed in
triplicate using at least three independently generated cDNA
samples. Results are expressed as the mean 6 standard error of the
mean (SEM). Relative gene expression was calculated as described
previously [17]. Alterations in gene expression were considered
significant at 1.5-fold change and p#0.05.
Antibody Generation and Purification
For analysis of human GPR109A and GPR109B, a custom,
commercial antibody was generated in rabbits using a synthetic
peptide (RHHLQDHFLEIDKKNC) to generate antisera recog-
nizing the N-terminus of GPR109A and GPR109B (Sigma-
Genosys, Woodlands, TX). Animal maintenance and antibody
production were performed by Sigma-Genosys according to the
protocol reviewed and approved by the Sigma-Genosys Institu-
tional Animal Care and Use Committee (IACUC), OPRR
Assurance A4182-01; USDA Registration Number 93-R-283.
Antisera were affinity-purified using Pierce’s Aminolink Kit
according to the manufacturer’s protocol (Rockford, IL). The
antibodies were validated by demonstrating that extracts from
HeLa cells, which do not express the receptor, did not show
positive immunoblots but extracts from HeLa cells (American
Type Culture Collection, Manassas, VA) transfected with the
nicotinic acid receptor did show positive bands at the expected
migration position. Additionally, CF3 cells that did not show
receptor expression by qRT-PCR also did not show positive
immunoblots. Also, all immunoblot analyses included a control
that showed that the peptide against which the antibodies were
generated competed out the signal.
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SDS-PAGE and Western blot analyses were performed as
described previously [18]. Adherent cell populations were lysed in
ice-cold lysis buffer (150 mM sodium chloride, 50 mM sodium
fluoride, 50 mM potassium phosphate, 40 mM sodium pyrophos-
phate, 500 mL Triton X-100, 100 mL SDS, 200 mL 1 M Tris-HCl
pH 7.4 in water and 1 tablet of complete mini protease inhibitor
cocktail, Roche Diagnostics, Indianapolis, IN) for 30 min at 4uC.
Lysates were then centrifuged at 12,000 rpm for 30 min at 4uC.
Protein concentration of the lysates was determined using the
BCA
TM Protein Assay Kit (Pierce, Rockford, IL) according to the
manufacturer’s instructions. Twenty micrograms of protein were
added to 46loading buffer (250 mM Tris pH 6.8, 8% SDS, 20%
glycerol, 0.012% bromophenol blue, 4% b-mercaptoethanol),
heated to 95uC for 5 min, electrophoresed in 12.5% SDS-
polyacrylamide gels, and transferred to PVDF membranes
(Amersham, Piscataway, NJ). All membranes were blocked for
1 h with 5% non-fat milk in Tris Buffered Saline (TBS) plus 0.1%
Tween-20 (10 mM TBS-T, pH 7.4) and incubated overnight at
4uC in primary antibody or in primary antibody plus 1000 molar
excess peptide (used to generate the antibody) relative to antibody,
incubated in 5% non-fat milk TBS-T 24 h prior to usage.
Membranes were incubated and developed in Immobilon
TM
Western Chemiluminescent HRP Substrate (Millipore, Billerica,
MA) according to manufacturer’s instructions. After initial
blotting, membranes were reprobed for b-actin (Sigma-Aldrich,
St. Louis, MO) to ensure even loading. Blots were scanned and
analyzed with ImageJ version 1.39u software (NIH, Bethesda,
MD). Values reported for target proteins were normalized to
the blots’ respective b-actin levels in at least three independent
experiments.
Immunocytochemistry (ICC)
CF3, NHEK, HaCaT, Ras-transformed HaCaT, A-431, and
SCC-25 cells were grown on coverslips. For fixation, cells were
rinsed twice with TBS, incubated in 4% formaldehyde in TBS for
30 min, and rinsed twice with TBS. To label the GPR109A/B
receptors, endogenous biotin blocking was performed using
NeutrAvidin
TM Biotin-Binding Protein (Pierce) for 30 min at
room temperature. Immediately after, the cells were incubated in
3% bovine serum albumin dissolved in TBS (BSA-TBS) blocking
buffer for 1 h and incubated overnight at 4uC with primary
antibody diluted in blocking buffer (1:10). For peptide competition
experiments, a 1000 fold excess of peptide was included. The
following day, cells were washed 3 times for 5 min each with TBS.
The blocking step was repeated and cells were incubated in 1:25
Biotin-SP-conjugated AffiniPure Goat Anti-Rabbit IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA) for 30 min at
37uC. Slides were washed with TBS and incubated in 1:25
Streptavidin Quantum Dot 605 Conjugates (Millipore) for 45 min
at 37uC. After thorough washes with TBS, coverslips were
mounted using mounting medium containing 90% glycerol and
10% TBS. The immunostained slides were placed at 4uC and
visualized the following day under a fluorescence microscope.
Immunohistochemistry (IHC)
Immunohistochemical detection of GPR109A/B was per-
formed on paraffin-embedded sections from normal human skin
biopsies. Archived material from a study conducted in accordance
with the Declaration of Helsinki Principles reviewed by Integ
Review Ethical Review Board, Austin, TX. All subjects read and
signed an IRB-approved Consent Form. All participants, those
administering the interventions, and those assessing the outcomes
were blinded to group assignment. Paraffin-embedded sections
were deparaffinized in xylene and hydrated in a graded series of
alcohol, sections were immersed in citric acid in a water bath at
87uC for 20 min to enhance antigen retrieval. Sections were then
rinsed in TBS and blocked in 3% BSA-TBS for 20 min.
Immediately after blocking, sections were incubated in primary
antibody in 3% BSA-TBS (1:10) overnight at 4uC. For peptide
competition experiments, a 1000 fold excess of peptide was
included. The following day, sections were washed in TBS,
blocked once again, and incubated in 1:25 Biotin-SP-conjugated
AffiniPure Goat Anti-Rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) for 30 min at 37uC. Sections were
rinsed with TBS and incubated in 1:25 Streptavidin Quantum Dot
605 Conjugates (Millipore) for 45 min at 37uC. After thorough
washes with TBS, coverslips were mounted using mounting
medium containing 90% glycerol and 10% TBS. For peptide
competition experiments, sections were washed in TBS and
incubated in 1:1000 FITC Goat Anti-Rabbit IgG (Jackson
ImmunoResearch Laboratories) for 1 h at RT.
IHC analysis of caspase 14 and filaggrin involved analogous
procedures using antibody SC5628 (Santa Cruz Biotechnology,
Santa Cruz, CA) for caspase 14 and 3137-500 (Abcam, Cam-
bridge, MA) for filaggrin. Quantification of antibody staining was
performed as described previously [5].
cAMP Assay
NHEK, HaCaT, Ras-transformed HaCaT, A-431, SCC-25,
and CF3 cells were seeded at a density of 25,000 cells in 35 mm
culture dishes. Two days later, culture medium was removed and
replaced with culture medium containing 6100 ng/mL pertussis
toxin (incubated overnight), 610 mM forskolin in the presence or
absence of nicotinic acid at different concentrations for 1 h prior
to testing. Except for dose response studies, the final concentration
of nicotinic acid used was 100 mM. Measurement of intracellular
cAMP levels was performed using cyclic AMP Complete EIA Kit
(Assay Designs, Ann Arbor, MI) per manufacturer’s instructions.
Experiments were repeated three times with independent cell
cultures. Data are presented as mean 6 SEM from three separate
experiments.
Results
Nicotinic acid promotes epidermal differentiation in
photodamaged human skin
Chronic UV exposure leads to impaired epidermal differenti-
ation and increased epidermal proliferation that can result in
actinic keratosis lesions and squamous cell cancers of the skin
[19]. We have previously concluded that myristyl nicotinate
(MN), a prodrug that delivers nicotinic acid to skin, promotes
epidermal differentiation with associated enhanced skin barrier
function in chronically photodamaged skin as judged by changes
in epidermal and stratum corneum thickness, decreased rates of
transepidermal water loss and increases in minimal erythemal
dose [5]. To examine effects of MN on differentiation more
directly, two epidermal differentiation markers, caspase 14 and
filaggrin [20] were assessed in subjects with skin photodamage in
a placebo controlled clinical trial [5]. Fig. 1A shows an example
of biopsy samples stained at baseline and after 12 weeks of topical
application of a formulation containing 5% MN and Fig. 1B
shows quantification of caspase 14 and filaggrin in subjects
treated with placebo or MN formulations. The presence of MN
results in an increase relative to placebo of approximately 30%
for caspase 14 and 20% for filaggrin. The placebo formulation
substituted myristyl myristate for MN, ruling out any effects of
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from the prodrug.
Nicotinic acid receptor genes are expressed in normal
human skin
The promotion of epidermal differentiation by nicotinic acid
led us to characterize the nicotinic acid receptors in human skin
as a putative nicotinic acid target. Genes encoding both high
affinity (GPR109A) and low affinity (GPR109B) forms of the
nicotinic acid receptor have been described previously and the
expression of these genes has been reported in skin [6,12,21]
but very minimal characterization has been reported. PCR
analysis revealed expression of genes encoding nicotinic acid
receptors in adipose tissue, place n t a ,a n dl u n g( F i g .2 A ) ,t i s s u e s
previously shown to express both receptor forms [6,7,8,10,12].
Fig. 2A also shows that transcripts for both high and low affinity
forms of the receptor were readily detected in human skin and
HaCaT cells. Very little signal was detected in CF3 dermal skin
fibroblasts (the bright partial signal shown for GPR109A likely
represents contamination from the HaCaT lane as it was not
observed in repeat experiments). The relative levels of
e x p r e s s i o ni nh u m a ns k i ne x a m i n e db yq R T - P C Rs h o wt h a t
the gene encoding the high affinity form of the receptor is
expressed at approximately 2.2 fold higher level than the low
affinity form (Fig. 2B).
Nicotinic acid receptor genes are over-expressed in
squamous cell skin cancers
The expression of both GPR109A and GPR109B relative to
that of normal skin was examined in squamous cell cancers
(SCC) of different stages of progression (Fig. 2C). Stage I SCC
samples show a slight increase in the mRNA expression of
GPR109A, whereas GPR109B mRNA expression is not signi-
ficantly elevated. In stage II and IIB tumors, GPR109A mRNA
expression is elevated approximately 3-fold while GPR109B
expression again remains similar to that of normal skin. In stage
III and in unstaged tumors graded as ‘‘invasive SCC’’,
both receptor expression profiles are elevated up to 16-fold
relative to normal human skin tissue. In general, increased
expression of the GPR109 genes increases with the stage of
cancer progression.
Nicotinic acid receptor genes are transcribed and
translated in skin cell lines
Various skin cell lines were examined by qRT-PCR for
GPR109A/B gene expression and the results were compared
relative to normal primary human epidermal keratinocytes
(NHEK). Immortalized epidermal keratinocytes (HaCaT cells),
tumorigenic epidermal keratinocytes (Ras-transformed HaCaT),
an epidermoid vulva carcinoma-derived cell line previously re-
ported to contain nicotinic acid receptors (A-431), and a human
squamous cell carcinoma cell line (SCC-25) express mRNA for
both receptors (Fig. 3A). Over-expression relative to NHEK is
observed up to 40-fold in skin cancer cells as compared to NHEK
(Fig. 3A). In contrast, expression of nicotinic acid receptors in
dermis-derived normal human diploid fibroblasts (CF3) is
undetectable.
To determine if nicotinic acid receptor transcripts are trans-
lated, we examined cell extracts for GPR109A/B protein using an
anti-peptide antibody developed and characterized in our
laboratory (See Materials & Methods). This antibody targets a
sequence near the N-terminus common to both receptors and does
not differentiate between the highly homologous GPR109A and
GPR109B proteins. Western blot analyses show that nicotinic acid
receptor protein was detected in all cell lines examined at the
expected size for the two nicotinic acid receptors (,42 kDa)
(Fig. 3B). The peptide used to generate the antibody effectively
competed the antibody signal, demonstrating antibody selectivity
(Fig. 3C). The amount of protein relative to b-actin is higher in the
Figure 1. Nicotinic acid promotes epidermal differentiation in photodamaged human skin. Tissue arrays of skin biopsy samples from a
clinical study of the effects of myristyl nicotinate (MN) in human subjects with photodamaged skin [5] were stained for the terminal differentiation
markers caspase 14 and filaggrin. Panel A: An example of a biopsy sample at baseline and 12 weeks of MN treatment stained with H&E, and
immunostaining for caspase 14 or filaggrin. Panel B: Quantification of staining for the placebo (n=27) and MN treated (n=31) groups for caspase 14
and filaggrin. Students t-test was used to compare placebo and MN treated groups and p values are shown.
doi:10.1371/journal.pone.0020487.g001
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compared to NHEK.
Nicotinic acid receptors in human skin are present in the
epidermis and hair follicle
To determine the cellular localization of GPR109A/B in
human skin, immunostaining analyses were performed. We
observed that GPR109A/B are expressed from the basal layer
through the spinous and granular layers of the epidermis and in
the hair follicles of normal human skin (Fig. 4A). Higher
magnification (Fig. 4B) reveals that GPR109A/B expression
appears to be more evenly distributed throughout the cell in the
basal cell layers of the epidermis and shows a more peripheral
distribution in the spinous and granular layers where keratinocytes
are in later stages of terminal differentiation. An alternative
fluorescent tag, Fluorescein isothiocyanate (FITC), for detecting
anti-peptide antibody binding is used in Fig. 4C to demonstrate
that peptide used to generate the antibody effectively blocked
binding in these tissues (Fig. 4D).
Nicotinic acid receptor cellular localization varies among
cultured epidermal cells
NHEK cells were stained using the anti-peptide antibody
(Fig. 5A) and peptide competition blocked the staining (Fig. 5B).
Staining appears on the periphery of aggregates of cells forming
‘‘cobblestone structures’’ while isolated cells appear to have a
more diffuse pattern of labeling (Fig. 5A). In HaCaT cells,
GPR109A/B expression is mainly localized to the periphery
(Fig. 5C). In contrast, in Ras-transformed HaCaT (Fig. 5D), A-
431 (Fig. 5E), and SCC-25 (Fig. 5F) the plasma membrane
localization is accompanied by labeling throughout the cyto-
plasm. Receptor expression in skin fibroblasts, CF3, is undetect-
able (data not shown).
Normal keratinocytes demonstrate a functional G protein
-coupled nicotinic acid receptor signaling through Gi
whose function is diminished in skin cancer cells
Most characterizations of the functionality of nicotinic acid
receptors have been studied in cells that do not inherently express
Figure 2. GPR109A and GPR109B are expressed in human tissues and cells including skin. Panel A: RT-PCR was performed on total RNA
from adipose tissue, placenta, lung, and skin tissues and cells using primers specific for GPR109A (top row) and GPR109B (bottom row) as described in
Materials and Methods. Panel B: qRT-PCR was performed on total RNA from six different normal human skin tissues using probes specific for
GPR109A (dark grey column) and GPR109B (light grey column) receptors as described in Material and Methods. Students t-test was used to compare
GPR109A to GPR109B, * p#0.05. Panel C: qRT-PCR analyses were performed on total RNA from ten human squamous cell carcinoma tissues using
probes specific for GPR109A (dark grey columns) and GPR109B (light grey columns) receptors. Results represent the mean 6 SEM. Students t-test was
used to compare to normal human skin, * p#0.05.
doi:10.1371/journal.pone.0020487.g002
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over-expressed. In our studies, we examined intrinsic receptor
functionality by measuring the ability of nicotinic acid to inhibit
forskolin-stimulated cAMP formation in the absence of heterolo-
gous expression. Under these conditions, the relative contribution
of nicotinic acid sensitive cAMP formation is less than that in
transfected cells. Forskolin treatment elicited cAMP formation in
all of the cells studied with an accumulation of 170–200 pmol
cAMP per mg protein in a 1 h incubation and the presence of
100 mM nicotinic acid inhibited the forskolin-induced cAMP
production differentially in the various cell types (Fig. 6A). The
relative degree of inhibition in the various cell lines by nicotinic
acid is shown in Fig. 6B. Inhibition of cAMP formation by
nicotinic acid through the intrinsic receptors was approximately
44% in NHEK cells, 43% in HaCaT and 39% in Ras-transformed
HaCaT cells. In contrast, cAMP stimulated by forskolin was
significantly reduced in the tumor-derived cells. Nicotinic acid
inhibited only 23% in A-431 cells and 13% in SCC-25 cells.
Forskolin treatment elicits significant cAMP accumulation in CF3
cells but nicotinic acid fails to inhibit cAMP formation, consistent
with the absence of nicotinic acid receptor expression observed in
dermal fibroblasts (Fig. 3A).
To determine whether the response to nicotinic acid is signaling
through the inhibitory Ga subunit and to further examine receptor
functionality in SCC-25 cells, cAMP production in NHEK and
SCC-25 was examined in the presence of pertussis toxin, a known
inhibitor of the heterotrimeric Gi protein subunit (Fig. 7). Pertussis
toxin completely abolished nicotinic acid-mediated inhibition of
forskolin-stimulated cAMP formation in NHEK cells. In contrast,
the response to nicotinic acid is very small in SCC-25 cells in the
absence or presence of pertussis toxin. These data indicate that the
nicotinic acid receptor(s) are signaling via Gi and further
demonstrate that the receptor has greatly reduced functionality
in SCC-25 cells.
To characterize receptor function further, we compared dose-
dependent inhibition by nicotinic acid of forskolin-induced
cAMP production in NHEK, HaCaT, and SCC-25 cells. Fig. 8
shows representative data and curves that fit the data to a two-
site binding model predicted for binding to high affinity and low
affinity receptors. Data from multiple experiments were fit to a
two-site model to calculate EC50 values for receptor affinity and
relative receptor abundance was assessed by the magnitude of
reduction of cAMP generation by nicotinic acid. The data was a
close fit to a two-site model for each cell line with R
2 values for
fit to the data points ranging from 0.985 to 0.988. NHEK cells
showed evidence of a significant abundance of both GPR109A
and GPR109B with EC50 values of 6.9 nM and 25 mM,
respectively (R
2 value of 0.985). Compared to NHEK, HaCaT
cells showed a reduced abundance of GPR109A with lower
affinity (EC50 of 72 nM) but a similar abundance and affinity of
GPR109B (EC50 of 17 mM) (R
2 value of 0.988). Compared to
NHEK, SCC-25 cells showed a greatly reduced abundance of
GPR109A and GPR109B, with calculated EC50 values of 36 nM
and 22 mM( R
2 v a l u eo f0 . 9 8 7 ) .T h eE C 50 value for the
endogenous GPR109A in NHEK is lower than that reported
previously but the other values for both GPR109A and
GPR109B are similar to the previously reported EC50 values
for GPR109A and GPR109B in cells transfected with the
recombinant receptors or from in vitro studies reported to be
approximately 100 nM and 100 mM, respectively [9]. These
Figure 3. GPR109A/B genes are transcribed and translated in human skin cells. Panel A: qRT-PCR was performed on total RNA from
normal human epidermal keratinocytes (NHEK), immortalized human epidermal keratinocytes (HaCaT), immortalized Ras-transformed human
epidermal keratinocytes (Ras-transformed HaCaT), human epidermoid carcinoma cells (A-431), squamous cell carcinoma cells (SCC-25), and human
diploid fibroblasts (CF3), using probes specific for GPR109A (dark grey columns) and GPR109B (light grey columns) receptors. Students t-test was
used to compare to NHEK, * p#0.05. Panels B and C: Protein Expression of GPR109A and GPR109B in Human Skin Cells. Cell extracts from NHEK
(lane 1), HaCaT (lane 2), Ras-transformed HaCaT (lane 3), A-431 (lane 4), and SCC-25 (lane 5) were subjected to SDS-PAGE and Western immunoblot
analyses using an antibody against GPR109A/B pre-incubated in the absence (panel B) or presence (panel C) of 1000-fold excess peptide against
which the antibody was generated relative to purified antibody. b-Actin was used as a loading control for Western immunoblot analyses. One
representative blot is shown of three independent experiments. The relative densities were quantified using ImageJ. Graphical representation shows
the average densitometric units of three independent experiments. Students t-test was used to compare to NHEK, * p#0.05.
doi:10.1371/journal.pone.0020487.g003
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have greatly reduced functionality in the tumor-derived SCC-25
cells.
Discussion
Pharmacological doses of nicotinic acid have long been known
to profoundly affect blood lipoproteins by decreasing low-density
lipoproteins (LDL) and very-low density lipoproteins (triglycerides)
and increasing high-density lipoproteins (HDL) [22,23]. More
recent studies have demonstrated pharmacological effects of
nicotinic acid in skin. Nicotinic acid can prevent both UV-
induced skin tumors and immune suppression in mice [24]. In
humans, nicotinic acid promotes epidermal differentiation in
photodamaged skin as assessed by increased epidermal and
stratum corneum thickness, enhanced barrier function, and
increased minimal erythemal dose [5]. We report here additional
evidence that nicotinic acid enhances epidermal differentiation as
measured by it effect on the terminal differentiation markers
caspase 14 and filaggrin (Fig. 1).
Studies of the pharmacological effects of nicotinic acid have
focused on nicotinic acid receptors GPR109A/B in humans [9].
These receptors have been mainly studied in the context of effects
on blood lipoproteins and associated skin flushing side effects of
oral nicotinic acid therapy [12]. While prior studies have surveyed
human tissues or cell lines for GPR109A mRNA expression
including skin [12,21,25], we describe here a more detailed
characterization of the nicotinic acid receptors in human skin and
skin-derived cells using qRT-PCR, Western blot, immunochem-
istry, and pharmacological analyses. Our studies show that
GPR109A/B genes are transcribed and translated in skin
keratinocytes and human skin epidermis (Figs. 2, 3, and 4A) but
that expression in dermal fibroblasts is below limits of detection.
Studies reported here provide several pieces of evidence that
support an in depth investigation of the hypothesis that
GPR109A/B is involved in the differentiation-promoting effects
Figure 4. Localization of GPR109A/B protein expression in human skin. Immunohistochemistry (IHC) analyses were performed on paraffin-
embedded human skin sections utilizing antibody against GPR109A/B. Panels A and B utilized Streptavidin Quantum Dot 605 Conjugates for
detection. Panels C and D used FITC Goat Anti-Rabbit IgG for detection. Panel A: Representative immunostaining sample shown at 2006
magnification. Panel B: Representative IHC sample shown at 4006magnification. Panels C and D: Representative IHC samples shown at 4006
magnification in the absence (Panel C) or presence (Panel D) of competition with peptide used to generate the antibody. Abbreviations: SC, stratum
corneum; SG, stratum granulosum; SS, stratum spinousum; SB, stratum basale. Size marker represents 2 microns.
doi:10.1371/journal.pone.0020487.g004
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of GPR109A/B expression in the epidermal layer of skin shows
a more diffuse cellular localization in basal keratinocytes and
a more peripheral membrane localization in areas of the epidermis
undergoing active differentiation (Fig. 4B), supporting the
possibility that the receptor is brought to the cell surface as
keratinocytes undergo differentiation. Similar results are seen for
normal keratinocytes in culture where isolated cells show a more
diffuse localization but ‘‘cobblestone’’ clusters of cells beginning to
differentiate show a more peripheral localization (Fig. 5A).
Second,endogenousGPR109A/Bisfunctionalinnormalhuman
keratinocytes in culture (Figs. 6, 7, 8). Most other studies that have
examined nicotinic acid receptors have used transfected cells not
inherently expressing GPR109A/B, although a previous study has
reported that the epidermoid cell line A-431 highly expresses
GPR109A and GPR109B receptors [25]. Even though this cell line
is not of skin origin, we included it in the studies described here
(Fig. 6). Our results corroborate the over-expression data of the
previous study. Our studies indicate that the endogenous GPR109A
has a higher affinity for nicotinic acid in NHEK cells compared to
results of other investigators using transfected cells and isolated
membranes but the affinity of GPR109A in HaCaT and GPR109B
in both NHEK and HaCaT is similar to that reported both for
transfectedcellsandisolatedmembranes[22].ForSCC-25cells,the
affinity of GPR109A is reduced compared to NHEK and the
abundance of both receptors is greatly reduced.
Third, our results indicate that abnormalities in GPR109A/B
transcription and function develop as progressive skin damage
Figure 5. Localization of GPR109A and GPR109B protein expression in cultured normal and malignant human skin cells. Panels A
and B: Immunocytochemistry (ICC) analyses utilizing an antibody against GPR109A/B were performed on NHEK shown in red and merged with
nuclear DAPI staining in blue. Panel A shows staining using the GPR109A/B antibody and Panel B shows staining in the presence of 1000 fold excess
of peptides used to raise the antibody. Panel C: HaCaT, Panel D: Ras-transformed HaCaT, Panel E: A-431, Panel F: SCC-25. For all panels,
magnification was 4006and size marker represents 10 microns.
doi:10.1371/journal.pone.0020487.g005
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The degree of over-expression of the GPR109A gene increases as
a function of disease progression in skin (Fig. 2C) and cultured
SCC-25 cells also significantly over-express the genes encoding the
receptors compared with normal keratinocytes (Fig. 3A). Further,
SCC-25 cells show an abnormal cellular localization (Fig. 5F) and
contain a nearly non-functional receptor (Figs. 6, 7, 8). The severe
reduction of functional cell surface receptors in SCC-25 cells may
be related to the observed over expression of the genes, where
increased mRNA levels represent an attempt to compensate for
the lack of functional protein on the cell surface. The epidermoid
carcinoma cell line, A-431, also shows reduced receptor function.
Our report of the loss of functional nicotinic acid receptors in
SCC-25 cells is of interest with regard to a previous study of the
potential role of GPR109A in colon cancer. Thangaraju et al. have
characterized the expression of GPR109A in colon tissues and
found expression in the lumen-facing apical membrane of colonic
and intestinal epithelial cells. However the receptor is silenced in
human colon cancers, in a mouse model of colon cancer, and in
colon cancer cell lines [26]. They also show that GPR109A
mediates the tumor suppressive effects of butyrate, a putative
ligand of GPR109A in the colon, suggesting that the GPR109A
Figure 6. GPR109A and GPR109B are functional in normal
human keratinocytes but are defective in malignant cells.
Panel A: NHEK, HaCaT, Ras-transformed HaCaT, A-431, SCC-25, and CF3
cells were treated in the presence of 10 mM forskolin (open columns) or
10 mM forskolin and 100 mM nicotinic acid (grey columns) for 1 h
followed by measurement of intracellular cAMP levels. Data are from
three independent experiments and show forskolin-induced cAMP
production relative to cellular protein. Panel B: The percent inhibition
by nicotinic acid is shown for each cell line. For both panels A and B,
Students t-test was used to compare cAMP produced without nicotinic
acid to that produced with nicotinic acid, * p#0.05.
doi:10.1371/journal.pone.0020487.g006
Figure 7. GPR109A/B couple through Gi in normal keratino-
cytes while SCC-25 cells are insensitive to pertussis toxin and
nicotinic acid. NHEK (open columns) and SCC-25 (grey columns) cells
were pretreated with or without 100 ng/mL pertussis toxin overnight
and stimulated with 10 mM forskolin in the presence or absence of
100 mM nicotinic acid and intracellular cAMP levels were measured.
Data represent the mean 6 SEM from three independent experiments
calculated as forskolin-induced cAMP relative to cellular protein.
Students t-test was used to compare to cAMP produced without
nicotinic acid to that produced with nicotinic acid, * p#0.05.
doi:10.1371/journal.pone.0020487.g007
Figure 8. Effect of increasing concentrations of nicotinic acid
on forskolin stimulated cAMP levels. NHEK (squares), HaCaT
(circles), and SCC-25 cells (triangles) were treated with different
concentrations of nicotinic acid the effects on cAMP levels were
determined. Representative data are shown with curve fitting lines
using a two site-binding model. The R
2 values for the curve fitting were
NHEK (0.985), HaCaT (0.988) and SCC-25 (0.987). EC50 values for
GPR109A and GPR109B, respectively, calculated by curve fitting of data
from multiple experiments were: NHEK (6.9 nM and 25 mM); HaCaT
(72 nM and 17 mM); SCC-25 (36 nM and 22 mM).
doi:10.1371/journal.pone.0020487.g008
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together with our data, suggest that a functional GPR109A/B may
be important in maintaining a differentiated state in epithelial cells
and that cancer cells may utilize different mechanisms to generate
a non-functional nicotinic acid receptor to avoid differentiation
signals mediated by the receptor. While butyrate is proposed as a
putative endogenous ligand of the receptor in the colon, the ketone
body ß-hydroxybutryate has been proposed as an endogenous
ligand in tissues [22]. ß-hydroxybutyrate would represent a logical
ligand in skin as it accumulates under conditions such as fasting or
starvation, where it could function to support skin barrier function
under stress conditions.
In summary, the increased epidermal differentiation in nicotinic
acid-treated human skin may involve nicotinic acid receptor-
mediated signaling pathways, although other mechanisms may
contribute to the effects of nicotinic acid on photodamaged skin.
Both forms of the receptor are expressed in human skin, appearing
mainly in the epidermis but are not present in the dermis. The
altered expression of the genes encoding GPR109A/B, the
abnormal pattern of cellular distribution, and impaired function-
ality of the receptor in squamous cell carcinoma cells suggest that
progression of skin damage leading to receptor defects could
provide a mechanism for squamous cell cancers to avoid
differentiation signals. However, the observation that poorly
differentiated keratinocytes can be driven to differentiate in the
presence of sufficient numbers of normal keratinocytes [4] raises
the possibility that treatments that could promote epidermal
differentiation in photodamaged skin could restore the balance of
proliferation and differentiation required for maintaining skin
homeostasis and thus may counteract the development of AK
lesions and SCC. In that context, nicotinic acid receptors could be
potential targets for skin cancer prevention. The studies reported
here provide sufficient evidence to justify genetic and pharmaco-
logic interventions to define whether and how the nicotinic acid
receptor family may function in promoting differentiation of
photodamaged skin.
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